DWA
NKTR icon

Douglass Winthrop Advisors’s Nektar Therapeutics NKTR Stock Holding History

Douglass Winthrop Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,800
Closed -$418K – 264
2014
Q4 		$418K Sell
1,800
-100
-5% -$21.4K 0.04% 145
2014
Q3 		$344K Sell
1,900
-33
-2% -$6.32K 0.03% 156
2014
Q2 		$372K Hold
1,933
– – 0.03% 143
2014
Q1 		$351K Sell
1,933
-67
-3% -$13.3K 0.03% 145
2013
Q4 		$340K Hold
2,000
– – 0.04% 142
2013
Q3 		$313K Buy
2,000
+67
+3% +$12.4K 0.04% 137
2013
Q2 		$335K Buy
+1,933
New +$296K 0.04% 132

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Douglass Winthrop Advisors's NKTR Position: Q1 2015 in Review

Douglass Winthrop Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2015, closing a stake of 1,800 shares — an estimated $418K sold.

Douglass Winthrop Advisors first reported a position in NKTR in Q2 2013 and held it in 7 quarters. The position peaked at $418K in Q4 2014. 153 funds tracked by Wall St. Rank hold NKTR as of Q1 2015.

  • Douglass Winthrop Advisors reported no remaining Nektar Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Douglass Winthrop Advisors sold 1,800 Nektar Therapeutics shares in Q1 2015, an estimated $418K.
  • Douglass Winthrop Advisors first reported a position in Nektar Therapeutics in Q2 2013 and held it in 7 quarters.
  • Douglass Winthrop Advisors's Nektar Therapeutics position peaked at $418K in Q4 2014.
  • 153 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2015.

Based on Douglass Winthrop Advisors's 13F filing for Q1 2015, filed 29 Apr 2015.